PE ratio relative to earnings growth — is the valuation justified?
0.41
PEG Ratio
0.41
Growth Rate Source
Good Data Quality5-Year EPS CAGR
Current Price
$21.42
TTM EPS
$4.10
P/E Ratio
5.22
Growth Rate
12.7%
5-Year EPS CAGR
Sector
Healthcare
Biotechnology
Calculated
8/18/2026
10:06:04 AM
Peer Comparison
Sample Size
2 peers
Industry Median PEG
167.24
25th Percentile
0.88
75th Percentile
333.61
INVA PEG (0.41) vs Industry Median (167.24): 100% discount
Symbol
Company
PEG
P/E
Growth
vs INVA
HALO
Halozyme Therapeutics, Inc.
0.88
19.9
22.7%
+113%
CORT
Corcept Therapeutics Incorporated
333.61
214.8
0.6%
+81068%
How to Interpret PEG Ratio
PEG < 1.0 — Potentially Undervalued. The stock may be priced below its earnings growth rate, suggesting a potential buying opportunity.
PEG 1.0–2.0 — Fairly Valued. The stock price is roughly in line with its earnings growth. A PEG of 1.0 is often considered "fair value."
PEG > 2.0 — Potentially Overvalued. The stock may be priced above what its earnings growth justifies.
Limitations:PEG ratios are less reliable for financial firms (earnings driven by interest margins), companies with negative/zero earnings growth, and hypergrowth companies (>100% growth) where the ratio may appear misleadingly low. Always use PEG alongside other valuation metrics.
